摘要
系统性硬化病是一种以皮肤及各系统胶原纤维硬化为主要特征的慢性自身免疫性疾病,以免疫调节、减少纤维化和改善血液循环为基础的传统疗法,但疗效欠佳.近年来愈来愈多的证据显示,T淋巴细胞、B淋巴细胞及多种细胞因子在系统性硬化病的发病中起重要作用.研究显示,依那西普、英夫利西单抗、利妥昔单抗等生物制剂治疗难治性系统性硬化病疗效显著.
Systemic sclerosis is a chronic autoimmune disease characterized by fibrosclerosis of the skin and various internal organs.Efficacy of traditional therapies based on immune regulation,reduction of fibrosis and improvement of blood circulation is usually poor.In recent years,more and more evidences have demonstrated that T lymphocytes,B lymphocytes and various cytokines play important roles in the pathogenesis of systemic sclerosis.Studies also have shown that biological agents such as etanercept,infliximab and rituximab have remarkable therapeutic effects on refractory systemic sclerosis.
出处
《国际皮肤性病学杂志》
2016年第2期68-71,共4页
International Journal of Dermatology and Venereology
关键词
硬皮病
系统性
关节炎
生物制剂
治疗应用
药物毒性
Scleroderma,systemic
Arthritis
Biological agents
Therapeutic uses
Drug toxicity
